» Articles » PMID: 33351111

The Evolution of Factor XI and the Kallikrein-kinin System

Overview
Journal Blood Adv
Specialty Hematology
Date 2020 Dec 22
PMID 33351111
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Factor XI (FXI) is the zymogen of a plasma protease (FXIa) that contributes to hemostasis by activating factor IX (FIX). In the original cascade model of coagulation, FXI is converted to FXIa by factor XIIa (FXIIa), a component, along with prekallikrein and high-molecular-weight kininogen (HK), of the plasma kallikrein-kinin system (KKS). More recent coagulation models emphasize thrombin as a FXI activator, bypassing the need for FXIIa and the KKS. We took an evolutionary approach to better understand the relationship of FXI to the KKS and thrombin generation. BLAST searches were conducted for FXI, FXII, prekallikrein, and HK using genomes for multiple vertebrate species. The analysis shows the KKS appeared in lobe-finned fish, the ancestors of all land vertebrates. FXI arose later from a duplication of the prekallikrein gene early in mammalian evolution. Features of FXI that facilitate efficient FIX activation are present in all living mammals, including primitive egg-laying monotremes, and may represent enhancement of FIX-activating activity inherent in prekallikrein. FXI activation by thrombin is a more recent acquisition, appearing in placental mammals. These findings suggest FXI activation by FXIIa may be more important to hemostasis in primitive mammals than in placental mammals. FXI activation by thrombin places FXI partially under control of the vitamin K-dependent coagulation mechanism, reducing the importance of the KKS in blood coagulation. This would explain why humans with FXI deficiency have a bleeding abnormality, whereas those lacking components of the KKS do not.

Citing Articles

Keratin 1 modulates intestinal barrier and immune response kallikrein kinin system in ulcerative colitis.

Dong X, Zhang Y, Luo J, Li M, Ma L, Qi Y World J Gastroenterol. 2025; 31(6):102070.

PMID: 39958441 PMC: 11752705. DOI: 10.3748/wjg.v31.i6.102070.


Green biosynthetic silver nanoparticles from as multifunctional hemostatic agents: Combining hemostasis, antibacterial, and anti-inflammatory properties for effective wound healing.

Li Y, Tan Y, Zhao H, Chen S, Nilghaz A, Cao R Mater Today Bio. 2025; 31:101468.

PMID: 39906203 PMC: 11791296. DOI: 10.1016/j.mtbio.2025.101468.


Plasma kallikrein supports FXII-independent thrombin generation in mouse whole blood.

Wan J, Dhrolia S, Kasthuri R, Prokopenko Y, Ilich A, Saha P Blood Adv. 2024; 8(12):3045-3057.

PMID: 38593231 PMC: 11215197. DOI: 10.1182/bloodadvances.2024012613.


Biochemical Approach to Poly(Lactide)-Copper Composite-Impact on Blood Coagulation Processes.

Mrozinska Z, Kudzin M, Ponczek M, Kaczmarek A, Krol P, Lisiak-Kucinska A Materials (Basel). 2024; 17(3).

PMID: 38591465 PMC: 10856769. DOI: 10.3390/ma17030608.


Pharmacologic targeting of coagulation factors XII and XI by monoclonal antibodies reduces thrombosis in nitinol stents under flow.

Keeling N, Wallisch M, Johnson J, Le H, Vu H, Jordan K J Thromb Haemost. 2024; 22(5):1433-1446.

PMID: 38331196 PMC: 11055672. DOI: 10.1016/j.jtha.2024.01.023.


References
1.
Semba U, Shibuya Y, Okabe H, Yamamoto T . Whale Hageman factor (factor XII): prevented production due to pseudogene conversion. Thromb Res. 1998; 90(1):31-7. DOI: 10.1016/s0049-3848(97)00307-1. View

2.
Juang L, Mazinani N, Novakowski S, Prowse E, Haulena M, Gailani D . Coagulation factor XII contributes to hemostasis when activated by soil in wounds. Blood Adv. 2020; 4(8):1737-1745. PMC: 7189277. DOI: 10.1182/bloodadvances.2019000425. View

3.
Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y, Kitamura N . Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem. 1993; 268(14):10024-8. View

4.
ZUCKER M, Zivelin A, Landau M, Rosenberg N, Seligsohn U . Three residues at the interface of factor XI (FXI) monomers augment covalent dimerization of FXI. J Thromb Haemost. 2009; 7(6):970-5. DOI: 10.1111/j.1538-7836.2009.03353.x. View

5.
Matafonov A, Sarilla S, Sun M, Sheehan J, Serebrov V, Verhamme I . Activation of factor XI by products of prothrombin activation. Blood. 2011; 118(2):437-45. PMC: 3138693. DOI: 10.1182/blood-2010-10-312983. View